The OIS Drug Delivery Forum was held virtually on December 2, 2021. Re-Vana CEO Michael O'Rourke delivered a virtual presentation about the Re-Vana technology. See the video on Vimeo by following this link, or watch it embedded below....
The purpose of article series from AdLib, ‘Product | People | Potential’ is to feature and showcase the very best UK start-ups with great potential, truly inspiring businesses that are shaking up their sector. We capture and share the stories behind the name. We...
In the first 2 articles of the Retina Times Innovation and Entrepreneurship section, we discussed how to secure your intellectual property (IP), define your business model, assemble your team, and develop a quality management system (QMS). Here, we discuss fund...
Sophie Bakri MD, Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN joins Re-Vana Scientific Advisory Board
New Appointments Bring Extensive Ocular Drug Delivery, Strategy and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into the Eye to Treat Sight-Threatening Eye Diseases Belfast, Northern Ireland – 23 February 2021 – Re-Vana...
In the OIS Podcast, ExSight Ventures discuss why they invested into Re-Vana. Here is the segment where they discuss Re-Vana Therapeutics: Download the excerpt using this link.Listen to the Full Podcast Here (Discussion of Re-Vana commences at 43 minutes.)...
Michael O’Rourke CEO presents online at the OIS Drug Delivery Forum – 5th November 2020
Michael O'Rourke, CEO of Re-Vana Therapeutics, presents online at the Ophthalmology Futures Forums on Wednesday, September 30th, 2020. https://youtu.be/iUBtmg7jCWo
Welcome to BusinessCloud’s Northern Ireland Tech 50 ranking for 2020. Cemetery software firm PlotBox tops our inaugural ranking of Northern Ireland’s most innovative technology companies. See Full Article at BusinessCloud >>
See the entire Opthamology Future Forum Advisory Board at: https://www.ophthalmology-futures.com/about-us/advisory-board/
Belfast, Northern Ireland – June 2, 2020 – Re-Vana Therapeutics Ltd, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, today announced that it has closed $3.25...
… The late-morning session, titled “New Horizons in Drug Delivery,” will focus exciting innovations in drug delivery systems, with moderators Michael Robinson, MD, vice president and Therapeutic Area head, Allergan; and James C. Tsai, MD, MBA, National Eye Health...